Summary
AbbVie Inc.'s third-quarter 2017 10-Q filing reveals a solid financial performance, demonstrating growth in net revenues and earnings. The company reported an 8.8% increase in worldwide net revenues to $7.0 billion for the quarter and a 9% increase to $20.5 billion for the first nine months of the year, primarily driven by the strong performance of Humira and Imbruvica. Diluted earnings per share for the nine months reached $3.27, up from $2.78 in the prior year period. The company also highlighted significant investments in its R&D pipeline, focusing on immunology, oncology, and neurology, with over 30 compounds in mid- to late-stage development. AbbVie continued to return value to shareholders through increased dividends and share repurchases, signaling confidence in its ongoing business strategy and future prospects.
Financial Highlights
53 data points| Revenue | $7.00B |
| Cost of Revenue | $1.62B |
| Gross Profit | $5.38B |
| SG&A Expenses | $1.46B |
| Operating Expenses | $4.30B |
| Operating Income | $2.69B |
| Interest Expense | $293.00M |
| Net Income | $1.63B |
| EPS (Basic) | $1.02 |
| EPS (Diluted) | $1.01 |
| Shares Outstanding (Basic) | 1.60B |
| Shares Outstanding (Diluted) | 1.60B |
Key Highlights
- 1AbbVie reported an 8.8% increase in net revenues to $6.995 billion for Q3 2017 and an 8.7% increase to $20.477 billion for the first nine months of 2017.
- 2Diluted earnings per share (EPS) increased to $1.01 for Q3 2017 and $3.27 for the nine months ended September 30, 2017, up from $0.97 and $2.78 respectively in the prior year.
- 3Humira remained a key revenue driver, with global sales increasing by 15% for the nine-month period, reaching $13.5 billion.
- 4Imbruvica demonstrated strong growth, with global sales up 41.2% for the nine-month period to $1.865 billion.
- 5Research and development expenses increased by 13% to $3.580 billion for the nine months ended September 30, 2017, reflecting continued investment in pipeline development.
- 6The company generated $7.376 billion in cash flow from operating activities for the first nine months of 2017.
- 7AbbVie announced an 11% increase in its quarterly cash dividend to $0.71 per share, payable in February 2018, and maintained a substantial stock repurchase program.